The effect of protease inhibitors on weight and body composition in HIV-infected patients

AIDS

Volumn 12, Issue 13, 1998, Pages 1645-1651

  Silva, Marisela ^a   Skolnik, Paul R ^a   Gorbach, Sherwood L ^a   Spiegelman, Donna ^b   Wilson, Ira B ^a   Fernández DiFranco, M Gabriela ^a   Knox, Tamsin A ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antiretroviral therapy; Body composition; HIV; Lean body mass; Protease inhibitor; Weight

Indexed keywords

PROTEINASE INHIBITOR;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY WEIGHT; CALORIC INTAKE; CLINICAL ARTICLE; DATA ANALYSIS; EXERCISE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEAN BODY WEIGHT; NUTRITION; PERCEPTION; PRIORITY JOURNAL; QUALITY OF LIFE; VIRUS LOAD; WEIGHT GAIN;

ADULT; BODY COMPOSITION; BODY WEIGHT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NUTRITIONAL STATUS; RITONAVIR; SAQUINAVIR; VIRAL LOAD;

EID: 0032505082     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199813000-00012     Document Type: Article

References (34)

1. Kotler DP, Wang J, Pierson Jr RN: Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr 1989, 50:1255.
2. kotler DP, Tierney AR, Wang J, Pierson RN Jr: Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 1989, 50:444.
3. Suttman U. Ockenga J, Selberg O, Hoogestraat L, Deicher H, Müller MJ: Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. J Acquir Immune Defic Syndr Hum Retroviruses 1995, 8:239-246.
4. Yarchoan R, Lietzau JA. Nguyen BY, et al.: A randomised pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic immunodeficiency virus infection. J Infect Dis 1994, 169:9-17.
5. Shepp DH, Ashraf A: Effect of didanosine on human immunodeficiency virus viremia and anligenemia in patients with advance disease: correlation with clinical response. J Infect Dis 1993, 167:30-35.
6. Oster MH, Enders SR, Samuels SJ, et al.: Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994, 121:400-408.
7. von Roenn JM, Armstrong D, Kotler DP, et al.: Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994, 121:393-399.
8. Hengge UR, Baumann M, Maleba R, et al.: Oxymetholone promotes weight gain in patients with advance human immunodeficiency virus (HIV-1) infection. Br J Nutr 1996, 75:129-138.
9. Markowitz M, Saag M, Powderly WG, et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV infection. N Engl J Med 1995, 333:1534-1539.
10. Deeks SG, Smith M, Holodniy M, Kahn JO: HIV-1 protease inhibitors. A review for clinicians. JAMA 1997, 277:145-153.
11. Schapiro JM, Winters MA, Stewart E, et al.: The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996, 124:1039-1050.
12. Katzenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200-500 CD4 cell per cubic millimeter. N Engl J Med 1996, 335:1091-1098.
13. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogs plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1977, 337:725-733.
14. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
15. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
16. Mouton Y. Alfandari S, Valette M, et al.: Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS-reference centres. AIDS 1997, 11:1101-1105.
17. Hsiang JL, Myers LU, Yen-Lieberman B, et al.: Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis 1994, 170:553-562.
18. Bozzette SA, Hays KD, Berry SH, Kanouse DE, Wu AW: Derivation and properties of a brief health status assessment instrument for use in HIV disease. J Acquir Immune Defic Synd Hum Retrovirol 1995, 8:253-265.
19. Zeger S, Liang KY: Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986, 42:121-130.
20. Durrleman S, Simon R: Flexible regression models with cubic splines. Stat Med 1989, 8:551-561.
21. Center for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41:RR-17.
22. Yarchoan R, Weinhold K, Lyerly HK, et al.: Administration of 3′-azido-3′-deoxythymidine, and inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986, I:575-580.
23. Schambelan M, Mulligan K, Grunfeld C, et al.: Recombinant human growth hormone in patients with HIV-associated wasting: a randomised, placebo-controlled trial. Ann Intern Med 1996, 125:873-882.
24. Waters D, Danska J, Hardy K, et al.: Recombinant human growth hormone, insuline-like growth factor 1, and combination therapy in AIDS-associated wasting. A randomized, double-blind, placebo-controlled trial. Ann Int Med 1996, 125:863-872.
25. Gold J, High HA, Li Y, et al.: Safely and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. AIDS 1996, 10:745-752.
26. Grunfels C, Kotler DP, Hamadeh R, Lierny A, Wang J, Pierson RN: Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989, 86:27-31.
27. Grunfeld C, Pang M, Doerrler W, et al.: Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74:1045-1052.
28. Hellerstein MK, Grunfeld C, Wu K, et al.: Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endrocrinol Metab 1993, 76:559-565.
29. Sullivan AK, Nelson MR: Marked hyperlipidaemia on ritonavir therapy [letter]. AIDS 1997, 11:938-939.
30. Engelson ES, Tierney AR, Pi-Sunyer FX, et al.: Effects of megestrol acetate upon body composition and circulating testosterone in patients with AIDS. J Acquir Immune Defic Syndr 1995, 9:1107.
31. Forbes G: Lean body mass-body fat interrelationships in humans. Nut Rev 1987, 45:225-231.
32. Wilson IB, Cleary PD: Clinical predictors of physical function in persons with acquired immune deficiency syndrome. Med Care 1996, 34:610-623.
33. Wilson IB, Cleary PD: Clinical predictors of declines in physical functioning in persons with AIDS: Results of a longitudinal study. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:343-349.
34. Roubenoff R, Suri J, Raymond J, Fauntlerov J, Gorbach SL: Feasibility of increasing lean body mass in HIV-infected adults using progressive resistance training. Presented at the Second International Conference on Nutrition-HIV infection. Cannes, France, 1997. Nutrition 1997, 13:271.